title: [Long-term follow-up of anatomic heart transplantation. Apropos of 60 patients with a mean follow-up of 36 months].
abstract: The aim of this study was to collect different problems seen in long-term evolution of patients who had anatomical cardiac transplantation and to compare with those seen in patients with standard transplantation. During the mean follow-up of 36 months, we analysed different data of 60 patients mean aged 51, who underwent anatomical cardiac transplantation. Six patients (10%) died within the 30 days after surgery. No patient needed the use of permanent pacemaker. Echocardiographic examination found normal atrial shape. One month after surgery, echocardiography described 16 tricuspid regurgitations (22.66%) and 8 mitral regurgitations (13.33%), 1 year later, there was respectively 13.33 and 6.66% tricuspid and mitral regurgitation. We had 8 late deaths: 1 sudden death, 2 chronic rejections, 1 pancreatitis and 4 cancers. The survival analysis pointed out 84% at 1 year, 80 at 2 years, 78 at 3 years and 73 at 5 years. Six months after surgery, 80% of patients were treated for high blood pressure; 85% had serum creatinine level equal or superior to 13 mg/L, with mean serum ciclosporin at 130 ng/mL. At the 3rd month, 6 endomyocardial biopsies were equal or superior to grade 2 rejection (International Society for Heart Transplantation). Between the 3rd and 12th month, 3 endomyocardial biopsies were equal or superior to grade 2 rejection, and the same between the 12th and 24th month. The infections rate was 0.8 episode per patient. Long term follow-up of anatomical cardiac transplantation faces the same problems as in standard cardiac transplantation. It is better to perform anatomical cardiac transplantation because of its early postsurgical advantages. Long term care is the same as in standard cardiac transplantation.
authors.affiliation: Service de chirurgie cardiovasculaire, CHU de Dijon, université de Bourgogne, Dijon.
authors.forename: E
authors.initials: E
authors.lastname: Tatou
authors.forename: P
authors.initials: P
authors.lastname: Charvre
authors.forename: M C
authors.initials: MC
authors.lastname: Gomes
authors.forename: J C
authors.initials: JC
authors.lastname: Eicher
authors.forename: R
authors.initials: R
authors.lastname: Brenot
authors.forename: M
authors.initials: M
authors.lastname: David
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D001706:Biopsy; D002423:Cause of Death; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000097:blood; D016757:Death, Sudden, Cardiac / Q000209:etiology; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000209:etiology; D016027:Heart Transplantation / Q000009:adverse effects* / Q000000981:diagnostic imaging / Q000379:methods; D006801:Humans; D006973:Hypertension / Q000209:etiology; D007166:Immunosuppressive Agents / Q000097:blood; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000000981:diagnostic imaging / Q000209:etiology; D009369:Neoplasms / Q000209:etiology; D010195:Pancreatitis / Q000209:etiology; D016019:Survival Analysis; D015996:Survival Rate; D014262:Tricuspid Valve Insufficiency / Q000000981:diagnostic imaging / Q000209:etiology
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine